Anheart Therapeutics Announces Exclusive License Agreement With Nippon Kayaku For Taletrectinib In Japan
Taletrectinib is a next-generation ROS1 tyrosine kinase inhibitor (TKI) being developed for the treatment of ROS1-positive non-small cell…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
31 Oct 23
Taletrectinib is a next-generation ROS1 tyrosine kinase inhibitor (TKI) being developed for the treatment of ROS1-positive non-small cell…
30 Oct 23
Under the partnership, Intas will develop and commercialise Henlius’ Hansizhuang in Europe and India, in exchange for €42m…
27 Oct 23
The collaboration will primarily leverage Verily's advanced molecular and real-world evidence solutions to support the development of Georgiamune's…
26 Oct 23
ZEN-3694 is the Zenith’s lead candidate, currently in clinical development for various oncologic indications and several studies sponsored…
25 Oct 23
The partnership allows Moderna to leverage Caris’ large-scale library of de-identified, multi-modal data and analytics capabilities to advance…
25 Oct 23
Combination of Elektrofi’s ultra-high concentration microparticle suspension technology platform and Lilly's therapeutic expertise could expand new frontiers in…
20 Oct 23
The deal includes Daiichi Sankyo’s patritumab deruxtecan (HER3-DXd), ifinatamab deruxtecan (I-DXd) and raludotatug deruxtecan (R-DXd) candidates
19 Oct 23
Stuart Therapeutics will get an upfront payment as well as development and sales-related milestone payments along with royalties…
19 Oct 23
Chagas disease is caused by the parasite Trypanosoma cruzi, which is primarily transmitted through a subspecies of blood-feeding…
18 Oct 23
The partnership will initially focus on Assembly Bio’s next-gen core inhibitor ABI-4334, intended for HBV, long-acting helicase-primase inhibitor…